Skye Bioscience Files 8-K
Ticker: SKYE · Form: 8-K · Filed: Oct 6, 2025 · CIK: 1516551
Sentiment: neutral
Topics: filing, disclosure, financials
TL;DR
Skye Bioscience dropped an 8-K on Oct 6th, check the financials and disclosures.
AI Summary
Skye Bioscience, Inc. filed an 8-K on October 6, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Emerald Bioscience, Inc. and Nemus Bioscience, Inc., is incorporated in Nevada and headquartered in San Diego, California.
Why It Matters
This filing provides an official update on the company's regulatory disclosures and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically contains standard disclosures and financial information without immediate significant operational changes.
Key Players & Entities
- Skye Bioscience, Inc. (company) — Registrant
- October 6, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- San Diego, CA (location) — Address of principal executive offices
- Emerald Bioscience, Inc. (company) — Former company name
- Nemus Bioscience, Inc. (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing for Skye Bioscience, Inc.?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits, as of October 6, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on October 6, 2025.
In which state is Skye Bioscience, Inc. incorporated?
Skye Bioscience, Inc. is incorporated in Nevada.
What is the principal executive office address for Skye Bioscience, Inc.?
The principal executive office address for Skye Bioscience, Inc. is 11250 El Camino Real, Suite 100, San Diego, CA 92130.
What were some of Skye Bioscience, Inc.'s former company names?
Skye Bioscience, Inc. was formerly known as Emerald Bioscience, Inc. and Nemus Bioscience, Inc.
Filing Stats: 537 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-10-06 08:18:06
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 SKYE Nasdaq Global Market Indicate
Filing Documents
- skye-20251006.htm (8-K) — 29KB
- a251006_skyexnrxp2topline.htm (EX-99.1) — 74KB
- 0001628280-25-044223.txt ( ) — 229KB
- skye-20251006.xsd (EX-101.SCH) — 2KB
- skye-20251006_def.xml (EX-101.DEF) — 2KB
- skye-20251006_lab.xml (EX-101.LAB) — 21KB
- skye-20251006_pre.xml (EX-101.PRE) — 12KB
- skye-20251006_htm.xml (XML) — 2KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 6, 2025, Skye Bioscience, Inc. (the "Company") issued a press release titled "Skye Bioscience Reports Topline CBeyond Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial". A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company intends to host a conference call and live webcast to discuss the results on October 6, 2025 at 8:00 a.m. E.T. The information under this Item 7.01, including Exhibit 99.1 hereto, is being furnished herewith and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated October 6, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SKYE BIOSCIENCE, INC. Dated: October 6, 2025 /s/ Punit Dhillon Name: Punit Dhillon Title: Chief Executive Officer